Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R Cogle

Showing results (81-90 of 137) with videos related to

Pageof 14
Sort By:
Leukemia Research Reports|April 21, 2015
Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndromeJessica M Schmit, Daniel J Turner, Robert A Hromas, et al.
Hematology/Oncology and Stem Cell Therapy|October 21, 2019
Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipientsForat Lutfi, William Paul Skelton Iv, Yu Wang, et al.
Clinical Medicine Insights. Oncology|September 19, 2014
Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II StudyMichael Byrne, Donya Salmasinia, Helen Leather, et al.
Transfusion|February 11, 2012
Characteristics of thawed autologous umbilical cord bloodEmma H Rosenau, Michele W Sugrue, Michael Haller, et al.
American Journal of Preventive Medicine|March 22, 2026
Building Public Health Leadership Capacity Through Community-Based Education: The Florida Health Policy Leadership AcademyChoeeta Chakrabarti, Jaclyn M Hall, Jennifer H LeLaurin, et al.
Obstetrics and Gynecology|October 19, 2023
Access to Prenatal Care Among Patients With Opioid Use Disorder in Florida: Findings From a Secret Shopper StudyKimberly Fryer, Chinyere N Reid, Amanda L Elmore, et al.
Leukemia Research|August 17, 2018
CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopeniaGuillermo Garcia-Manero, Bart L Scott, Christopher R Cogle, et al.
Stem Cells (Dayton, Ohio)|October 8, 2005
Developmental differences in megakaryocyte maturation are determined by the microenvironmentWilliam B Slayton, David A Wainman, Xiao Miao Li, et al.
Neoplasia (New York, N.Y.)|December 2, 2011
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrowAnnet Kirabo, Sung O Park, Anurima Majumder, et al.
The American Journal of Pathology|July 17, 2012
The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosisAnnet Kirabo, Sung O Park, Heather L Wamsley, et al.
Pageof 14

Showing results (81-90 of 137) with videos related to

Sort By:
Pageof 14
Leukemia Research Reports|April 21, 2015
Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndromeJessica M Schmit, Daniel J Turner, Robert A Hromas, et al.
Hematology/Oncology and Stem Cell Therapy|October 21, 2019
Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipientsForat Lutfi, William Paul Skelton Iv, Yu Wang, et al.
Clinical Medicine Insights. Oncology|September 19, 2014
Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II StudyMichael Byrne, Donya Salmasinia, Helen Leather, et al.
Transfusion|February 11, 2012
Characteristics of thawed autologous umbilical cord bloodEmma H Rosenau, Michele W Sugrue, Michael Haller, et al.
American Journal of Preventive Medicine|March 22, 2026
Building Public Health Leadership Capacity Through Community-Based Education: The Florida Health Policy Leadership AcademyChoeeta Chakrabarti, Jaclyn M Hall, Jennifer H LeLaurin, et al.
Obstetrics and Gynecology|October 19, 2023
Access to Prenatal Care Among Patients With Opioid Use Disorder in Florida: Findings From a Secret Shopper StudyKimberly Fryer, Chinyere N Reid, Amanda L Elmore, et al.
Leukemia Research|August 17, 2018
CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopeniaGuillermo Garcia-Manero, Bart L Scott, Christopher R Cogle, et al.
Stem Cells (Dayton, Ohio)|October 8, 2005
Developmental differences in megakaryocyte maturation are determined by the microenvironmentWilliam B Slayton, David A Wainman, Xiao Miao Li, et al.
Neoplasia (New York, N.Y.)|December 2, 2011
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrowAnnet Kirabo, Sung O Park, Anurima Majumder, et al.
The American Journal of Pathology|July 17, 2012
The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosisAnnet Kirabo, Sung O Park, Heather L Wamsley, et al.
Pageof 14